# IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

> **NCT03758781** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Cancer
- Recurrent Cancer
- Solid Tumor
- Renal Cell Carcinoma
- Urothelial Carcinoma
- NSCLC
- Squamous Cell Carcinoma
- Non-Small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** IRX 2
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03758781
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-13
- **Primary completion:** 2021-02-21
- **Final completion:** 2021-08-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758781, "IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03758781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*